



## BioLineRx to Report First Quarter 2012 Results on May 15, 2012

May 8, 2012 1:46 PM IDT

For Hebrew convenience translation, please click link below:

[Hebrew version](#)

**Jerusalem, Israel, May 8, 2012** --- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the three-months ended March 31, 2012 on Tuesday, May 15, 2012, before the U.S. markets open.

The Company will host a conference call on Tuesday, May 15 at 10:00 a.m. EDT featuring remarks by Kinneret Savitsky, Ph.D., CEO of BioLineRx, and Philip Serlin, Chief Financial and Operating Officer of BioLineRx. The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx's website, [www.biolinerx.com](http://www.biolinerx.com), and [www.kcsa.com](http://www.kcsa.com). Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. To dial into the conference call, please dial 1-888-281-1167 from the U.S. or +972-3-918-0644 internationally.

A replay of the conference call will be available approximately two hours after completion of the live conference call at [www.biolinerx.com](http://www.biolinerx.com) or [www.kcsa.com](http://www.kcsa.com). A dial-in replay of the call will be available until May 18, 2012; please dial 1-888-295-2634 from the U.S. or +972-3-925-5918 internationally.

### About BioLineRx

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx's current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase 2/3 study; BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc., is currently undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions has completed a Phase 1/2 study; BL-1021 for neuropathic pain is in Phase 1 development and BL-7040 for treating Inflammatory Bowel Disease (IBD) is commencing Phase 2. In addition, BioLineRx has 11 products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx's business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government's Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase 3) and commercialization. For more information on BioLineRx, please visit [www.biolinerx.com](http://www.biolinerx.com).

### Contacts:

Garth Russell / Todd Fromer  
KCSA Strategic Communications  
1 212-896-1250 / 1 212-896-1215  
[grussell@kcsa.com](mailto:grussell@kcsa.com) / [tfromer@kcsa.com](mailto:tfromer@kcsa.com)

Tsipi Haitovsky  
Public Relations  
+972-3-6240871  
[tsipih@netvision.net.il](mailto:tsipih@netvision.net.il)